Login to Your Account


LONDON – The EMA has released new guidelines for companies developing drugs to treat Alzheimer's disease, reflecting increased understanding of disease pathology and the availability of new diagnostic tools and biomarkers.

OXFORD, U.K. – The increasing level of funding dedicated to the commercialization of university research is indicative of progress, but the U.K. is not quite there in terms of translating knowledge that is the fruit of publicly funded research into real benefits.

LONDON – Actelion Ltd. added a positive EMA opinion to the FDA and Health Canada approvals for its first-in-class, selective prostacyclin IP receptor agonist, Uptravi (selexipag), for treating pulmonary arterial hypertension (PAH).

More EUROPE Headlines

Cast Your Vote

Should there be restrictions on the use of gene-editing technology?: